Lindus Health, the "anti-CRO" running radically faster, more  reliable clinical trials for life science pioneers, and Quotient Sciences, a leading global  clinical development and manufacturing accelerator, have announced a strategic partnership  to enable innovative biotech and pharma sponsors with enhanced patient recruitment for  Phase I-IIa clinical studies and a seamless pathway from first-in-human (FIH) to proof-of concept (POC) trials.  

The drug development process has traditionally required companies to engage multiple  vendors across pre-clinical and clinical phases, creating inefficiencies, knowledge gaps, and  operational delays. Lindus Health and Quotient Sciences partnership directly addresses this  industry challenge by combining Quotient's specialized early clinical and drug development  capabilities with Lindus’ proven patient recruitment expertise and later-stage trial delivery.  The outcome is a cohesive development continuum for customers, championed by trusted,  experienced partners who are agile and committed to accelerating the delivery of new  treatments to patients.  

Quotient Sciences conducts more than 70 Phase I studies per year across its clinics in the  US and UK, specializing in FIH to POC programs and a range of clinical pharmacology  studies. The company's unique Translational Pharmaceutics® model integrates drug product  development with early clinical capabilities, enabling rapid progression from formulation to  FIH. Early phase studies increasingly require specific patient populations, including  challenging cohorts that extend beyond traditional healthy volunteers. Through this  partnership, Lindus provides comprehensive patient recruitment support with an omni channel approach, access to over 40 million electronic medical records (EMRs), and a  widespread site network. Lindus Health has an established track record of delivering 73%  faster enrollment across all studies, enabling Quotient Sciences to execute efficient, high quality Phase I-IIa trials involving patients.  

Lindus Health brings extensive Phase II trial experience and end-to-end trial delivery  capabilities across the US, UK, and Europe, spanning multiple therapeutic areas, including  respiratory, neuropsychiatry, cardiometabolic, dermatology, and more. Together, the  companies offer a streamlined approach to clinical development, eliminating the need to  independently source and vet separate Phase I and later-stage CROs. The result is reduced  administrative burden, accelerated timelines, and more focus for sponsors on advancing  their science rather than managing vendors.  

"This partnership underscores our commitment to removing bottlenecks in the clinical  development lifecycle," said Michael Young, Co-CEO of Lindus Health. "By collaborating  with Quotient Sciences, we are creating a comprehensive development pathway that allows  biotech companies to move through a contiguous experience from FIH studies through to  pivotal trials. Sponsors get the specialized Phase I expertise they need at the beginning, with  recruitment support from the same proven end-to-end CRO partner ready to scale their  programs as they progress.” 

“Early-phase programs increasingly demand patient cohorts and rapid iteration, and Quotient  is addressing this industry need. By pairing Lindus Health’s recruitment engine with our early  clinical development expertise and Translational Pharmaceutics® platform, sponsors can  move seamlessly from first-in-human into later-stage trials with fewer handoffs, clearer  decision-making, and materially shorter timelines,” said Matt Paterson, Chief Strategy  Officer, Quotient Sciences.  

This collaboration is essential to eliminating traditional barriers in patient recruitment and  reducing friction when transitioning between development stages and CRO partners,  ultimately accelerating the delivery of breakthrough treatments to patients.